Interestingly, when the same analysis was repeated after segregating patients with NB based on the presence or absence of MYCN amplification, we observed a similar trend for nMNA but not MNA tumors (Supplemental Figure 1E), a result that cannot be explained by differences in BMX expression between nMNA and MNA tumors (Supplemental Figure 1F) but rather suggest that BMX expression may be a selective clinical indicator for patients with NB lacking MYCN amplification. This evidence concerns the gene BMX and neuroblastoma.